Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $94.36 USD
Change Today +5.16 / 5.78%
Volume 1.4M
INCY On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1801 Augustine Cut-Off

Wilmington, DE 19803

United States

Phone: 302-498-6700


Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. JAKAFI JAKAFI became commercially available in the United States in 2011 and is being marketed in the United States through its own specialty sales force and its commercial team, which has relevant expertise in the promotion, distribution and reimbursement of oncology drugs. To help ensure that all eligible MF patients have access to JAKAFI, the company has established a patient assistance program called IncyteCARES (CARES stands for Connecting to Access, Reimbursement, Education and Support). IncyteCARES helps ensure that any patient with intermediate or high-risk MF who meets certain eligibility criteria and is prescribed JAKAFI has access to the product regardless of ability to pay and has access to ongoing support and educational resources during treatment. In addition, IncyteCARES works closely with payers to help facilitate insurance coverage of JAKAFI. JAKAFI is distributed primarily through a limited network of specialty pharmacy providers and group purchasing organizations that allow for delivery of the medication by mail directly to patients or direct delivery to the patient's pharmacy of choice. Novartis received approval for JAKAVI in the European Union and Canada in 2012. JAKAVI is approved in approximately 50 countries with additional worldwide regulatory filings underway. Strategy The company’s strategy is to develop and commercialize its compounds on its own in selected markets, such as in myelofibrosis, other myeloproliferative neoplasms and other oncology indications. Research and Development As of December 31, 2013, the company incurred research and development expenses of $260.4 million. Regulation Research and Development: The company’s ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to regulation by governmental authorities in the United States and other countries. Regulation of Manufacturing Process: The company and its third-party manufacturers are subject to current Good Manufacturing Practices, which are regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by the FDA and the European Medicines Agency. Health Law Compliance: In addition to FDA laws and regulations, the company must also comply with various federal and state laws pertaining to healthcare ‘fraud and abuse’ which govern, among other things, its relationships with healthcare providers, and the marketing and pricing of prescription drug products. Significant Events Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in a Phase I/II study. History Incyte Corporation was founded in 1991.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $94.36 USD +5.16

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $8.39 USD +0.22
Array BioPharma Inc $7.40 USD +0.07
Evotec AG €3.71 EUR -0.034
GlaxoSmithKline SAE £12.00 EGP 0.00
Infinity Pharmaceuticals Inc $14.35 USD -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation INCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at